In a recent issue of Alzheimer's Research & Th erapy, we read with great interest the discussion by Szigeti and Doody [1] of including early-onset Alzheimer's disease (EOAD) (under age 65) in clinical trials. Successful enroll ment is a challenge in most Alzheimer's disease (AD) trials, and permitting the participation of these young motivated patients could aid recruitment. EOAD can be categorized as AD caused by autosomal dominant mutations (ADAD) in the amyloid precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) genes and as AD in individuals not known or suspected to harbor such mutations, which we here refer to as sporadic AD (SAD).
We agree with the authors that SAD cases under age 65 should be included in AD trials. Th e literature describing these cases does not suggest that clinical or biological diff erences warrant exclusion. We take pause, however, with the recommendation of categorical enrollment of ADAD patients in trials. Inclusion of persons with ADAD should be dependent upon the nature of the causative mutation, the drug under investigation, and the study objectives. More than 200 AD-causing mutations are known, and predicting the impact of all disease-causing mutations on drug effi cacy is diffi cult. APP muta tions are most frequent in the β-and γ-secretase cleavage regions and result in increases in the levels of both Aβ 42 and Aβ 40 , Aβ 42 alone, or the ratio of Aβ 42 to Aβ 40 [2, 3] . Aβ 40 resultant from processing of mutated APP is resis tant to degradation by neprilysin [4, 5] . γ-Secretase inhibitors may lack effi cacy in preventing APP cleavage by enzymes resultant from mutated PSEN genes [6, 7] . On pathological examination, the brains of persons with ADAD can demonstrate atypical morphology, distribu tion, and composition of Aβ deposits [2] . Biological diff er ences between ADAD and SAD might manifest similar diff erences in response or side-eff ect profi le to a given intervention and thus should be considered care fully before patients with ADAD are enrolled in trials.
In phase I studies, biological diff erences between ADAD and SAD could translate to diff erent dose requirements since younger patients with ADAD are likely to have a more rapid drug metabolism. Females may also be premenopausal, making teratogenicity a consideration. In phase II, diff erences in ADAD could have eff ects on outcomes and interpretation since ADAD participants might be overrepresented, given that the percentage of SAD patients who qualify for trials is low, ADAD patients have fewer barriers to participation, and trials are often conducted at academic centers where ADAD is studied. Alternatively, persons with ADAD might theoretically be enrolled in larger late-stage trials with a predefi ned plan to analyze effi cacy and safety of this AD subtype separately. Acceptance of this approach by regulatory bodies and willingness of sponsors to risk an impact on the overall trial signifi cance, however, are uncertain.
Th e Dominantly Inherited Alzheimer's Network and the Alzheimer's Prevention Initiative are preparing to conduct prevention clinical trials in ADAD, in part addressing the important need for clinical drug research in this population. Th ese studies may not enroll persons already demented with ADAD. In accordance with the principle of benefi cence, AD trial design should permit exami nation of effi cacy in all possible disease-suff ering popula tions. For every study, however, substantial consideration must be given to the issues of whether to include specifi c persons with ADAD and of how the data will be analyzed when the study is complete.
